Clinical Trial Update: Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A combined phase 1/2 trial evaluating gemcitabine, cisplatin, and lenalidomide as first-line therapy for metastatic urothelial carcinoma (urinary bladder neopla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Bladder Neoplasms
• Urothelial Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Urinary Bladder Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2014-11-26